Skip to main content Skip to main navigation Skip to search Skip to footer

Patient Enablement Programs for Clinical Trial Adherence

Patient Enablement Programs for Clinical Trial Adherence

Drugs don’t work in patients who don’t take them”. This statement is pertinent not just for the drugs launched, but also for test drugs in a Clinical Trial setting. Patient adherence is a critical component in a clinical trial as it directly impacts validity of the clinical trial data. It also plays a pivotal role in deciding the outcome of clinical trials – in determining the drug’s efficacy and in receiving regulatory approval to launch the drug after establishing dosing guidelines. Patient adherence affects not only pharmaceutical manufacturers from a spend point of view, but also the scientific and regulatory community. This paper aims to analyze the mechanisms of non-adherence in a clinical trial scenario, its implications on the trial outcome, and HCL’s role in designing trial-specific Patient Enablement Programs (PEP) to combat non-adherence.

DOWNLOAD THE WHITEPAPER

Contact Us
MAX CHARACTERS: 10,000

We will treat any information you submit with us as confidential. Please read our privacy statement for additional information.

We will treat any information you submit with us as confidential. Please read our privacy statement for additional information.